No, it assumes that some of us may not want to be immunosuppressed. You're making it sound like there's only one version of ME/CFS.
I think there are variations in ME, as in any illness, but I think it's one illness - or at least, that all correctly diagnosed patients share a final common pathway producing symptoms. There are probably a variety of initial triggers. Some appear to be infections, some vaccines, some even appear to be toxic exposures (such as organophosphates, like the Countess of Mar).
And although rituximab is generally an immunosuppressant, it doesn't have to be. It's easy to envision a scenario
One can imagine such things, but there is no evidence that it's immunostimulatory in any patients to date, and it seems mechanistically unlikely. One can postulate a way any drug can do anything - one can imagine a lot of things, but that's not science unless it's tested. What is known about rituximab universally points to it having immunosuppressive properties. The burden of proof is on the person suggesting otherwise.
I think you've mentioned a number of times that you don't experience fatigue
No, I have never said that. I don't believe fatigue is the right word to describe ME though, and I do not believe it defines the illness. I think it's more appropriately described as delayed onset exertional intolerance. Fatigue is found in many illnesses. Exertional intolerance is found in other illnesses - such as heart disease - but it is immediate onset, not delayed. Delayed onset exertional intolerance is unique to ME, and is pathognomic for the illness. Having fatigue does not mean one has ME - but Fluge and Melle are only taking patients in the trial who meet the CCC.
So it doesn't make sense to me that you would cite to the ME/CFS rituximab trials for your personal condition
I meet the canadian consensus criteria for ME. I don't believe in the use of the term CFS - I think it's just a poor attempt to define an illness that was already defined much better and much earlier. Fluge and Melle are using the CCC as well. Most serious researchers who have a clue about ME are using the CCC - very few now use Fukuda or Oxford (I think Wessely still likes Oxford...) F&M require all patients to have "Post exertional malaise and/or fatigue" - as per the CCC.
"Evidence of ongoing, active and clinically relevant infection" is listed as an exclusion criterion for participants in the RituxME Phase III trial, as is "Known immunodeficiency with risk from therapeutic B-cell depletion, such as hypogammaglobulinemia." This is because it's too risky to treat them with immunosuppressants like rituximab that are known to exacerbate existing infections and increase the risk of new ones. So anyone who has active infection cannot compare themselves to the RituxME trial.